$0.65
-0.04 (-5.96%)
Open$0.71
Previous Close$0.69
Day High$0.72
Day Low$0.65
52W High$6.19
52W Low$0.49
Volume—
Avg Volume33.2K
Market Cap57.65M
P/E Ratio—
EPS$-0.47
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+4,813.1% upside
Current
$0.65
$0.65
Target
$31.94
$31.94
$22.24
$31.94 avg
$42.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 15.40M | 13.64M | 13.89M |
| Net Income | -704,326 | -740,627 | -795,931 |
| Profit Margin | -4.6% | -5.4% | -5.7% |
| EBITDA | -1,183,474 | -997,072 | -1,062,628 |
| Free Cash Flow | -738,508 | -859,127 | -679,392 |
| Rev Growth | +4.1% | +16.3% | -0.4% |
| Debt/Equity | 0.22 | 0.30 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |